VIP

What is VIP?#

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide first isolated from porcine small intestine by Sami Said and Viktor Mutt in 1970. Originally identified based on its potent vasodilatory properties, VIP has since been recognized as a pleiotropic signaling molecule with far-reaching roles in the nervous system, immune system, gastrointestinal tract, cardiovascular system, and endocrine regulation. It belongs to the secretin/glucagon superfamily of peptides, which also includes pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, glucagon, and growth hormone-releasing hormone (GHRH), all of which share structural homology and signal through related class B G-protein coupled receptors.

VIP is widely distributed throughout the central and peripheral nervous systems, where it functions as a neurotransmitter, neuromodulator, and neurotrophic factor. In the brain, VIP-containing neurons are found in the cerebral cortex, hippocampus, hypothalamus (particularly the suprachiasmatic nucleus, the master circadian clock), amygdala, and brainstem. In the peripheral nervous system, VIP is a major neuropeptide of parasympathetic and sensory neurons innervating the gastrointestinal tract, respiratory tract, urogenital system, and blood vessels.

The VIP gene (located on chromosome 6q25) encodes a 170-amino acid preproprotein that is processed to yield VIP along with a related peptide, peptide histidine methionine (PHM-27) in humans or peptide histidine isoleucine (PHI) in rodents. Both VIP and PHM/PHI are co-released from neurons and exert overlapping but distinct biological effects through shared receptor systems.

Despite decades of research demonstrating its diverse biological activities and therapeutic potential, VIP has not achieved regulatory approval for any indication. Its clinical development has been hampered by its extremely short circulating half-life (approximately 1-2 minutes due to rapid enzymatic degradation), lack of receptor subtype selectivity, and broad tissue distribution leading to dose-limiting hypotension. Research continues to focus on developing stable VIP analogs and targeted delivery systems to overcome these pharmacological limitations.

Mechanism of Action#

Receptor Signaling: VPAC1 and VPAC2#

VIP exerts its biological effects primarily through two receptor subtypes: VPAC1 (also designated VIPR1) and VPAC2 (VIPR2). Both are class B (secretin family) G-protein coupled receptors that signal predominantly through Gs-alpha coupling to activate adenylate cyclase, generating intracellular cAMP. The resulting cAMP-dependent activation of protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac) mediates the majority of VIP's downstream effects.

VPAC1 is widely expressed in the lung, liver, gastrointestinal tract, thymus, and brain, and is the dominant VIP receptor on T lymphocytes, macrophages, and dendritic cells. It binds VIP and PACAP with approximately equal affinity (Kd in the low nanomolar range). VPAC2 has a more restricted expression pattern, with high levels in smooth muscle, the suprachiasmatic nucleus, thalamus, pancreatic acinar cells, and mast cells. VPAC2 also binds both VIP and PACAP, but with somewhat different downstream signaling kinetics.

In addition to the canonical Gs/cAMP pathway, VIP receptor activation can engage secondary signaling cascades depending on the cellular context. These include Gq-mediated phospholipase C (PLC) activation and calcium mobilization, particularly through VPAC2 in certain cell types; PI3K/Akt signaling, which mediates some of VIP's anti-apoptotic and neuroprotective effects; and MAPK/ERK pathway activation, contributing to cell proliferation and differentiation responses.

A third receptor, PAC1, binds PACAP with high affinity but VIP with 100-1000 fold lower affinity, and therefore plays a minimal role in VIP signaling at physiological concentrations.

Vasodilation Mechanism#

VIP is among the most potent endogenous vasodilators known. Its vasodilatory action is mediated through both direct smooth muscle relaxation and endothelium-dependent mechanisms. In vascular smooth muscle, VPAC1/VPAC2 receptor activation increases cAMP, which activates PKA. PKA phosphorylates myosin light chain kinase (MLCK), reducing its affinity for calcium-calmodulin and thereby inhibiting the contractile machinery. PKA also activates potassium channels (particularly large-conductance calcium-activated potassium channels, BKCa), causing membrane hyperpolarization and further relaxation.

Additionally, VIP stimulates endothelial nitric oxide synthase (eNOS) in vascular endothelial cells, promoting nitric oxide (NO) release, which diffuses to adjacent smooth muscle cells and activates soluble guanylate cyclase (sGC), generating cGMP. The combined cAMP- and cGMP-mediated smooth muscle relaxation produces robust vasodilation across multiple vascular beds, with the pulmonary, cerebral, coronary, and mesenteric circulations being particularly responsive.

In the airways, VIP acts as a primary non-adrenergic non-cholinergic (NANC) inhibitory neurotransmitter, producing bronchodilation through analogous cAMP-dependent smooth muscle relaxation. VIP-immunoreactive nerve fibers are abundant in airway smooth muscle, submucosal glands, and pulmonary vasculature, and VIP deficiency has been implicated in the pathogenesis of asthma and pulmonary arterial hypertension.

Neuroprotective Effects#

VIP has demonstrated neuroprotective properties across multiple experimental models, including excitotoxicity, oxidative stress, beta-amyloid toxicity, and ischemia-reperfusion injury. The neuroprotective mechanisms involve several parallel pathways.

Through VPAC receptor activation and cAMP/PKA signaling, VIP upregulates the expression of anti-apoptotic proteins Bcl-2 and Bcl-xL while suppressing pro-apoptotic Bax and caspase-3 activation. This shifts the cellular balance away from apoptosis in neurons exposed to cytotoxic insults. VIP also stimulates the release of neurotrophic factors, including brain-derived neurotrophic factor (BDNF), activity-dependent neuroprotective protein (ADNP), and neurotrophin-3, from glial cells. The neuroprotective protein ADNP, whose expression is directly regulated by VIP, has itself been shown to have potent neuroprotective effects and is essential for brain development.

In models of neuroinflammation, VIP reduces microglial activation and production of neurotoxic mediators including TNF-alpha, IL-1-beta, reactive oxygen species, and nitric oxide from iNOS. This anti-neuroinflammatory effect involves suppression of NF-kB signaling in activated microglia and promotion of microglial polarization toward an anti-inflammatory phenotype.

Immune Regulation#

VIP acts as a potent anti-inflammatory and immunomodulatory agent, providing a critical interface between the nervous and immune systems. The mechanisms of immune regulation include several key pathways.

In macrophages, VIP suppresses LPS-induced production of TNF-alpha, IL-6, IL-12, and NO through inhibition of NF-kB and AP-1 transcriptional activity. These effects are mediated primarily through VPAC1 and the cAMP/PKA pathway, which phosphorylates and stabilizes IkB-alpha, preventing NF-kB nuclear translocation. VIP also promotes macrophage production of the anti-inflammatory cytokine IL-10.

In dendritic cells, VIP inhibits maturation and reduces expression of co-stimulatory molecules and MHC class II, generating tolerogenic DCs that promote regulatory T-cell (Treg) differentiation rather than effector T-cell activation. VIP-conditioned dendritic cells have been shown to induce antigen-specific tolerance in experimental autoimmune models.

In T lymphocytes, VIP promotes the differentiation of Th2 cells while inhibiting Th1 polarization, and enhances the generation and function of CD4+CD25+FoxP3+ regulatory T cells. This Th2 shift and Treg promotion contribute to VIP's anti-inflammatory effects in autoimmune disease models.

Gut-Brain Axis and Circadian Regulation#

VIP plays a critical role in the gut-brain axis, serving as both a neurotransmitter in the enteric nervous system and a signaling molecule in the central regulation of gastrointestinal function. In the enteric nervous system, VIP is released from intrinsic inhibitory motor neurons and mediates receptive relaxation of the stomach, relaxation of sphincters, and regulation of intestinal secretion. VIP stimulates electrolyte and water secretion in the intestinal epithelium, contributing to the regulation of luminal fluid balance.

In circadian biology, VIP is expressed at high levels in the suprachiasmatic nucleus (SCN), where it is essential for maintaining synchrony among individual oscillator neurons. VIP-expressing neurons in the SCN communicate through VPAC2 receptors to synchronize circadian firing patterns across the nucleus. Genetic deletion of VIP or VPAC2 in mice results in disrupted circadian rhythms, abnormal sleep-wake cycles, and loss of coherent locomotor activity patterns. VIP signaling in the SCN is also involved in the entrainment of the circadian clock to light-dark cycles and the transmission of circadian timing information to downstream target tissues.

Therapeutic Applications and Clinical Evidence#

Pulmonary Arterial Hypertension#

Pulmonary arterial hypertension (PAH) is among the most clinically investigated applications of VIP. Patients with idiopathic PAH have been found to have reduced VIP expression in lung tissue and reduced serum VIP levels compared to healthy controls. In a small open-label study, inhaled VIP (100-200 micrograms daily for 3 months) in 20 patients with PAH produced significant improvements in mean pulmonary arterial pressure (reduction of approximately 13 mmHg), pulmonary vascular resistance, cardiac output, and 6-minute walk distance. These effects were accompanied by improvements in right ventricular function assessed by echocardiography.

However, a subsequent randomized, double-blind, placebo-controlled Phase 2 trial of inhaled aviptadil (synthetic VIP) in PAH failed to demonstrate statistically significant improvements in primary hemodynamic endpoints, dampening initial enthusiasm. The discrepancy between open-label and controlled trial results may reflect placebo effects, differences in drug delivery, or the limitations of VIP's pharmacokinetic profile even when administered by inhalation.

Acute Respiratory Distress and COVID-19#

During the COVID-19 pandemic, intravenous aviptadil was investigated for the treatment of respiratory failure associated with SARS-CoV-2 infection. The rationale was based on VIP's anti-inflammatory properties, its high concentration in pulmonary tissue, and its capacity to protect alveolar type II cells from cytokine-mediated injury. A Phase 2/3 trial (ZYESAMI trial) evaluated intravenous aviptadil in patients with COVID-19-associated respiratory failure requiring high-flow nasal cannula, non-invasive ventilation, or mechanical ventilation.

Preliminary results reported improvements in oxygenation and trends toward reduced mortality in the aviptadil group, but the trial did not meet its primary endpoint of survival without the need for mechanical ventilation at day 28 across all patient subgroups. An FDA Emergency Use Authorization application was submitted but not granted. This experience highlighted both the therapeutic potential and the translational challenges of VIP-based therapies.

Inflammatory Bowel Disease#

VIP has demonstrated efficacy in preclinical models of inflammatory bowel disease, including trinitrobenzene sulfonic acid (TNBS)-induced colitis and dextran sodium sulfate (DSS)-induced colitis in mice. In these models, VIP administration reduced colonic inflammation, decreased production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12, IFN-gamma), increased anti-inflammatory IL-10, and promoted mucosal healing. The therapeutic effects were associated with induction of regulatory T cells and tolerogenic dendritic cells in the colonic mucosa.

Clinical translation has been limited by VIP's pharmacokinetic challenges. However, the development of long-acting VIP analogs and targeted delivery systems, including VIP-loaded nanoparticles and microparticles designed for oral or rectal administration, represents an active area of research aimed at overcoming these barriers.

Neurodegenerative Disease Research#

VIP and its analog stearyl-norleucine-VIP (SNV) have shown neuroprotective efficacy in animal models of Alzheimer disease, Parkinson disease, and cerebral ischemia. In transgenic Alzheimer mouse models, VIP administration reduced beta-amyloid plaque burden, decreased neuroinflammation, and improved cognitive performance in behavioral assays. In Parkinson disease models (6-OHDA and MPTP), VIP protected dopaminergic neurons from degeneration and preserved motor function.

The neuroprotective peptide ADNP, whose expression is regulated by VIP, has emerged as an independent therapeutic target. Davunetide (NAP), an 8-amino acid fragment of ADNP, has undergone clinical trials for neurodegenerative conditions, representing an indirect validation of VIP's neurotrophic signaling pathway.

Evidence Gaps and Limitations#

Pharmacokinetic Barriers#

The single most significant limitation of VIP as a therapeutic agent is its extremely short circulating half-life of approximately 1-2 minutes. Rapid degradation by neutral endopeptidase (NEP), aminopeptidases, and serine proteases in plasma and tissues necessitates continuous infusion or specialized delivery systems to achieve sustained therapeutic concentrations. This pharmacokinetic profile has been the primary barrier to clinical translation despite decades of preclinical evidence supporting therapeutic efficacy.

Lack of Receptor Selectivity#

VIP activates both VPAC1 and VPAC2 receptors with similar affinity, yet these receptors mediate distinct and sometimes opposing biological effects in different tissues. The inability to selectively target one receptor subtype limits therapeutic precision and contributes to off-target effects. For example, VPAC1 activation on immune cells may be desirable for anti-inflammatory applications, but concurrent VPAC2-mediated effects on smooth muscle and metabolic tissues may produce undesired vasodilation and gastrointestinal effects. Development of receptor-selective VIP analogs is an active but challenging area of medicinal chemistry research.

Dose-Limiting Hypotension#

The potent vasodilatory activity of VIP, while therapeutically relevant for conditions such as pulmonary hypertension, represents a dose-limiting adverse effect for systemic applications. Intravenous VIP administration commonly produces flushing, hypotension, and reflex tachycardia, restricting the doses that can be safely administered. This narrow therapeutic window has complicated clinical development across all indications.

Limited Clinical Trial Data#

Despite extensive preclinical evidence spanning over five decades, the number of well-designed, adequately powered randomized controlled trials evaluating VIP or VIP analogs in human disease is very small. The PAH, COVID-19, and related trials represent the most advanced clinical investigation, but results have been mixed and no regulatory approval has been achieved. The gap between preclinical promise and clinical reality reflects both the pharmacological challenges described above and the difficulty of translating a pleiotropic, rapidly degraded neuropeptide into a viable therapeutic product.

Incomplete Understanding of Receptor Dynamics#

While the canonical cAMP/PKA signaling downstream of VPAC receptors is well characterized, the roles of non-canonical signaling pathways (PLC/calcium, PI3K/Akt, MAPK/ERK), receptor oligomerization, receptor desensitization, and biased agonism in mediating VIP's diverse tissue-specific effects remain incompletely understood. A more detailed understanding of these signaling dynamics could inform the design of next-generation VIP analogs with improved therapeutic profiles.

Safety of Long-Term Administration#

There are no long-term safety data for chronic VIP administration in humans. As a pleiotropic neuropeptide involved in immune regulation, circadian rhythms, and cell proliferation, the potential consequences of prolonged exogenous VIP exposure, including effects on immune surveillance, tumor biology, and neuroendocrine function, are largely unknown and represent a significant evidence gap.

Key Research Findings#

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension, published in Journal of Clinical Investigation (Petkov V et al., 2003; PMID: 12727925):

• The study demonstrated mean pulmonary arterial pressure decreased by of 13 mmHg

Related Reading#

• VIP research studies and evidence
• VIP dosing protocols
• VIP side effects profile
• Kisspeptin research guide